Stent to Treat Malignant Biliary Obstruction

The stent has been cleared by the U.S. Food and Drug Administration (FDA).

The major symptoms of malignant biliary obstruction result from the failure of bile to reach its proper destination. The placement of a stent can often alleviate this condition. The new stent, called Sentinol, is the product of Boston Scientific Corp. (Boston, MA, USA). Sentinol expands the company's family of self-expanding biliary stents, which includes the Wallstent endoprosthesis and the Symphony.

With the addition of Sentinol, Boston Scientific now offers self-expanding stents in diameter sizes ranging from 5-24 mm, offering options for matching a stent to a given set of procedural demands.

"This product launch complements our existing stent portfolio and reflects Boson Scientific's commitment to developing new technology for the peripheral intervention world,” said Paul LaViolette, senior vice president and group president, cardiovascular.
The company develops and markets medical devices whose products are used in a broad range of interventional medical specialties.




Related Links:
Boston Scientific